aPTT Mixing Studies

aPTT Mixing Studies, also known in the context of activated partial thromboplastin time (aPTT), partial thromboplastin time (PTT), or cephalin-kaolin time, are used to investigate a prolonged aPTT by separating factor deficiency states (such as hemophilia A or B or combined factor deficiencies) from inhibitor-mediated prolongation (including lupus anticoagulant or specific factor inhibitors) and by assessing for heparin effect. The test supports evaluation of intrinsic pathway disorders, workup of bleeding diathesis, and preoperative assessment of bleeding risk in patients with an elevated baseline aPTT. Baseline aPTT is also used to monitor unfractionated heparin therapy.

The aPTT primarily reflects activity of the intrinsic pathway components—high‑molecular‑weight kininogen, prekallikrein, and factors XII, XI, and VIII—and is less responsive to changes in the common pathway factors X and V, prothrombin, and fibrinogen. Prolonged aPTT results correlate with bleeding risk, whereas shortened values may be associated with a hypercoagulable tendency. The aPTT is commonly used for monitoring unfractionated heparin. Lupus anticoagulant–sensitive reagents are employed in this panel. Mixing studies yield interpretable results only when the patient’s aPTT is ≥5 seconds above the upper reference limit. The assay is more sensitive to deficiencies in intrinsic pathway factors than to those in the common pathway. An acute‑phase elevation of factor VIII can normalize a mildly prolonged aPTT and mask an underlying coagulation defect.